Valuation : Insmed Incorporated

Market Cap 25.89B 22.31B 20.91B 19.09B 35.97B 2,474B 36.08B 248B 96.81B 1,249B 97.19B 95.08B 4,141B P/E 2026 *
-74.9x
P/E 2027 * 109x
Enterprise Value 25.26B 21.76B 20.4B 18.63B 35.09B 2,414B 35.2B 242B 94.45B 1,218B 94.82B 92.76B 4,040B EV / Sales 2026 *
14x
EV / Sales 2027 * 8.57x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-2.35%
1 week-5.75%
Current month+20.22%
1 month+13.84%
3 months+9.38%
6 months-20.62%
Current year-31.89%
1 week 117.15
Extreme 117.15
127.18
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.64
Extreme 21.645
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Fiscal year

Chief Operating Officer

719,550 0.3320%
8/6/26 Fiscal year

Chief Technology Officer

81,519 0.0376%
Change 5-day change 1-year change 3-year change Capi.($)
-2.35%-5.75%-12.17%+448.29% 25.89B
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
-1.83%+3.29%+22.09%+195.17% 12.33B
Average -2.00%-1.40%+55.58%+192.68% 29.43B
Weighted average by Cap. -1.93%-1.30%+55.68%+154.60%

Financials

2026 *2027 *
Net sales 1.81B 1.56B 1.46B 1.33B 2.51B 173B 2.52B 17.32B 6.76B 87.15B 6.78B 6.63B 289B 2.89B 2.49B 2.33B 2.13B 4.01B 276B 4.02B 27.66B 10.79B 139B 10.84B 10.6B 462B
Net income -349M -301M -282M -258M -485M -33.39B -487M -3.35B -1.31B -16.86B -1.31B -1.28B -55.89B 211M 182M 171M 156M 294M 20.21B 295M 2.03B 791M 10.2B 794M 777M 33.82B
Net Debt -632M -544M -510M -466M -878M -60.38B -881M -6.06B -2.36B -30.48B -2.37B -2.32B -101B -1.16B -997M -934M -853M -1.61B -111B -1.61B -11.09B -4.33B -55.8B -4.34B -4.25B -185B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-28 US$118.54 -2.35% 1,977,867
26-08-27 US$121.39 -2.41% 1,056,260
26-08-26 US$124.39 +0.40% 1,979,984
26-08-25 US$123.89 -0.07% 2,373,321
26-08-24 US$123.98 -1.42% 1,341,042
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
118.54USD
Average target price
200.18USD
Spread / Average Target
+68.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock